Evidence map›Paper›PMID 25198467›Full record

ArticlePloS one2014

Influence of fenofibrate treatment on triacylglycerides, diacylglycerides and fatty acids in fructose fed rats.

Thomas Kopf, Hans-Ludwig Schaefer, Martin Troetzmueller, Harald Koefeler, Mark Broenstrup, Tatiana Konovalova, Gerd Schmitz

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Fructose and hepatic insulin resistance.Critical reviews in clinical laboratory sciences · 2020
    Review
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Thomas KopfInstitute for Clinical Chemistry and Laboratory Medicine, University Hospital Regensburg, Regensburg, Germany.
Hans-Ludwig SchaeferSanofi-Aventis Germany, R&D DIAB Div./Biomarker & Diagnostics, Frankfurt, Germany.
Martin TroetzmuellerCore Facility Mass Spectrometry, ZMF, Medical University Graz, Graz, Austria.
Harald KoefelerCore Facility Mass Spectrometry, ZMF, Medical University Graz, Graz, Austria.
Mark BroenstrupSanofi-Aventis Germany, R&D DIAB Div./Biomarker & Diagnostics, Frankfurt, Germany.
Tatiana KonovalovaInstitute for Clinical Chemistry and Laboratory Medicine, University Hospital Regensburg, Regensburg, Germany.
Gerd SchmitzInstitute for Clinical Chemistry and Laboratory Medicine, University Hospital Regensburg, Regensburg, Germany.
University Hospital Regensburg · DEMedical University of Graz · ATSanofi (Germany) · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Fenofibrate (FF) lowers plasma triglycerides via PPARα activation. Here, we analyzed lipidomic changes upon FF treatment of fructose fed rats. Three groups with 6 animals each were defined as control, fructose-fed and fructose-fed/FF treated. Male Wistar Unilever Rats were subjected to 10% fructose-feeding for 20 days. On day 14, fenofibrate treatment (100 mg/kg p.o.) was initiated and maintained for 7 days. Lipid species in serum were analyzed using mass spectrometry (ESI-MS/MS; LC-FT-MS, GC-MS) on days 0, 14 and 20 in all three groups. In addition, lipid levels in liver and intestine were determined. Short-chain TAGs increased in serum and liver upon fructose-feeding, while almost all TAG-species decreased under FF treatment. Long-chain unsaturated DAG-levels (36:1, 36:2, 36:4, 38:3, 38:4, 38:5) increased upon FF treatment in rat liver and decreased in rat serum. FAs, especially short-chain FAs (12:0, 14:0, 16:0) increased during fructose-challenge. VLDL secretion increased upon fructose-feeding and together with FA-levels decreased to control levels during FF treatment. Fructose challenge of de novo fatty acid synthesis through fatty acid synthase (FAS) may enhance the release of FAs ≤ 16:0 chain length, a process reversed by FF-mediated PPARα-activation.

Indexed as

AnimalsDiglyceridesFatty AcidsFenofibrateFructoseMaleRatsRats, WistarTriglyceridesDiglyceridesFatty AcidsFenofibrateFructoseTriglycerides

Identifiers

PMID25198467
PMCPMC4157811
OpenAlexW1988663018

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.